HAVCR2 and neoplasm: Emerging evidence has shown that cetuximab treatment in HNSCC can lead to the upregulation of PD-1 and T cell immunoglobulin and mucin domain protein-3 (TIM-3) expression in CD8+ tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment.